Global R&D Pipeline
My Favorite
Hot Targets:
IGF1R
Back
Total number of drugs
133
Phase II and later clinical stages
16.5%
Involving companies
157
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trofinetide | Trofinetide | Synthetic peptide | Nervous System Diseases Congenital Disorders Other Diseases | IGF-1R agonists | Walter Reed Army Institute of Research | ACADIA Pharmaceuticals, Inc. | Approved | - | United States Canada | 2023-03-10 | - | Fast Track（United States） Orphan Drug（European Union） Orphan Drug（United States） Priority Review（United States） Rare Pediatric Disease（United States） Priority Review（Canada） Orphan Drug（Japan） | - | - | - | - | Trofinetide | - | - | detail > | |
| Teprotumumab N01 | Teprotumumab N01 | Monoclonal antibody | Immune System Diseases Congenital Disorders Endocrinology and Metabolic Disease Eye Diseases | IGF-1R antagonists | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Biologics, Inc. Innovent Biologics (Suzhou) Co. Ltd. | Approved | Approved | China Macao | 2025-03-11 | 2025-03-11 | Priority Review（China） | - | - | - | - | Teprotumumab N01 | - | - | detail > | |
| Mecasermin Rinfabate | Mecasermin Rinfabate | Growth factors | Nervous System Diseases Cardiovascular Diseases Congenital Disorders Eye Diseases Respiratory Diseases Other Diseases | IGF-1R antagonists | Insmed, Inc. | Oak Hill Bio Corp. | Phase 2 | Pending (in Phase 2/3) | - | 2005-12-12 | - | Orphan Drug（European Union） Orphan Drug（United States） | - | - | - | - | Mecasermin Rinfabate | - | - | detail > | |
| NA-931 | NA-931 | Small molecule drug | Endocrinology and Metabolic Disease | GCGR agonists GIPR agonists GLP-1R agonists IGF-1R agonists | Biomed Industries, Inc. | Biomed Industries, Inc. | Phase 2/3 | - | - | - | - | - | - | - | - | - | NA-931 | - | - | detail > | |
| Linsitinib | Linsitinib | Small molecule drug | Immune System Diseases Congenital Disorders Endocrinology and Metabolic Disease Eye Diseases Neoplasms Skin and Musculoskeletal Diseases Other Diseases Digestive System Disorders | IGF-1R antagonists INSR inhibitors | Astellas Pharma, Inc. | Sling Therapeutics, Inc. Tongji University The Johns Hopkins University School of Medicine | Phase 2/3 | Discovery | - | - | - | Orphan Drug（United States） | - | - | - | - | Linsitinib | - | - | detail > | |
| VRDN-003 | VRDN-003 | Monoclonal antibody | Immune System Diseases Congenital Disorders Endocrinology and Metabolic Disease Eye Diseases | IGF-1R antagonists | Viridian Therapeutics, Inc. | Viridian Therapeutics, Inc. Zai Lab (Shanghai) Co., Ltd. | Phase 3 | Phase 3 | - | - | - | - | - | - | - | - | VRDN-003 | - | - | detail > | |
| Veligrotug | Veligrotug | Monoclonal antibody | Immune System Diseases Congenital Disorders Endocrinology and Metabolic Disease Eye Diseases | IGF-1R antagonists | ImmunoGen, Inc. | Zenas BioPharma LLC. Viridian Therapeutics, Inc. Shanghai Zenas Biotechnology Co., Ltd. | NDA/BLA | Phase 1/2 | - | - | - | Breakthrough Therapy（United States） | - | - | - | - | Veligrotug | - | - | detail > | |
| Conteltinib | Conteltinib | Small molecule drug | Neoplasms Respiratory Diseases Digestive System Disorders Endocrinology and Metabolic Disease | ALK inhibitors IGF-1R antagonists PYK2 inhibitors | Centaurus Biopharma Co Ltd | Shouyao Holdings (Beijing) Co. Ltd. Centaurus Biopharma Co Ltd Zhejiang University Beijing SL Pharmaceutical Co., Ltd. | NDA/BLA | NDA/BLA | - | - | - | - | - | - | - | - | Conteltinib | - | - | detail > | |
| Teprotumumab-TRBW | Teprotumumab-TRBW | Monoclonal antibody | Immune System Diseases Congenital Disorders Endocrinology and Metabolic Disease Eye Diseases Neoplasms Skin and Musculoskeletal Diseases Other Diseases | IGF-1R antagonists | Genmab A/S | Amgen Europe BV Amgen Ltd. Amgen Australia Pty Ltd. Amgen, Inc. Roche Diagnostics GmbH Horizon Therapeutics Ireland DAC | Approved | Phase 1 | United States European Union Japan United Kingdom Australia Iceland Liechtenstein Norway | 2020-01-21 | - | Breakthrough Therapy（United States） Fast Track（United States） Orphan Drug（United States） Priority Review（Australia） Orphan Drug（Japan） | - | - | - | - | Teprotumumab-TRBW | - | - | detail > | |
| Brigatinib | Brigatinib | Small molecule drug | Neoplasms Respiratory Diseases Nervous System Diseases Congenital Disorders Otorhinolaryngologic Diseases Skin and Musculoskeletal Diseases Other Diseases Immune System Diseases Hemic and Lymphatic Diseases | ALK inhibitors EGFR antagonists FLT3 inhibitors IGF-1R antagonists ROS1 inhibitors | ARIAD Pharmaceuticals, Inc. | Takeda Pharmaceutical Co., Ltd. Takeda Pharma SA Takeda Pharmaceuticals Korea Co., Ltd. Takeda Pharma A/S ARIAD Pharmaceuticals, Inc. Takeda Pharmaceutical (China) Co. Ltd. Takeda Pharmaceuticals Australia Pty Ltd. Takeda Pharmaceuticals U.S.A., Inc. | Approved | Approved | United States China European Union Japan Australia Iceland South Korea Liechtenstein Norway | 2017-04-28 | 2022-03-22 | Accelerated Approval（United States） Breakthrough Therapy（United States） Orphan Drug（United States） | - | - | - | - | Brigatinib | - | - | detail > |
Total 133 data
1
2
3
4
5
6
...
13
14
